Quarterly report pursuant to Section 13 or 15(d)

Stock-based Compensation

v3.8.0.1
Stock-based Compensation
3 Months Ended
Mar. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Disclosure of Compensation Related Costs, Share-based Payments
12. Stock-based Compensation
 
In June 2017, the Company’s stockholders approved an amendment of the Company’s Amended and Restated 2014 Equity Incentive Plan (the “2014 Plan”) to increase the number of shares available for grant by 1,000 shares.  The total shares authorized for grant under the 2014 Plan is 4,714.
 
On October 30, 2017, the Board approved an amendment to the 2014 Plan to increase the maximum number of shares of common stock that may be issued under the 2014 Plan by 4,400 shares, from 4,714 to 9,114 shares (the “2014 Plan Amendment”) effective as of the time such amendment is approved by the stockholders. At the December Special Meeting, a proposal was submitted to be voted on by the stockholders to approve the 2014 Plan Amendment contingent on the approval by the stockholders of the Authorized Capital Amendment. The proposal was approved by the stockholders at the December Special Meeting, with approximately 25,205 shares voted for, 2,955 shares voted against, and 356 shares abstaining. However, since the proposal was contingent on the approval by the stockholders of the Authorized Capital Amendment, management has solicited stockholders to ratify the 2014 Plan Amendment at the 2018 Annual Meeting. Further information is provided in the 2018 Proxy Statement.
 
As of March 31, 2018, there were 5,162 shares available for future awards after taking into account the 2014 Plan Amendment.
 
Stock Options
 
The following table summarizes information about the Company’s stock options outstanding at March 31, 2018, and activity during the three months then ended:
 
 
 
 
 
 
 
 
 
Weighted-
 
 
 
 
 
 
 
 
 
 
 
 
Average
 
 
 
 
 
 
 
 
 
Weighted-
 
Remaining
 
Aggregate
 
 
 
Stock
 
Average
 
Contractual
 
Intrinsic
 
 
 
Awards
 
Exercise Price
 
Life (Years)
 
Value
 
Balance as of December 31, 2017
 
 
3,156
 
$
4.96
 
 
 
 
 
 
 
Options granted
 
 
38
 
$
1.83
 
 
 
 
 
 
 
Options exercised
 
 
-
 
$
-
 
 
 
 
 
 
 
Options forfeited
 
 
(289)
 
$
5.19
 
 
 
 
 
 
 
Options cancelled
 
 
(7)
 
$
4.45
 
 
 
 
 
 
 
Balance as of March 31, 2018
 
 
2,898
 
$
4.89
 
 
6.90
 
$
297
 
Vested and expected to vest at March 31, 2018
 
 
2,898
 
$
4.89
 
 
6.90
 
$
297
 
Exercisable as of March 31, 2018
 
 
1,851
 
$
6.10
 
 
5.66
 
$
50
 
 
As of March 31, 2018, total unrecognized compensation cost related to unvested stock options was $1,809. This amount is expected to be recognized as stock-based compensation expense in the Company’s condensed consolidated statements of operations and comprehensive income over the remaining weighted average vesting period of 2.29 years.
 
The per-share fair value of each stock option was determined on the date of grant using the Black-Scholes option pricing model using the following assumptions:
 
 
 
Three months ended March 31,
 
 
 
2018
 
2017
 
 
 
 
 
 
 
 
 
Dividend yield
 
 
 
 
 
Risk-free interest rate
 
 
2.74
%
 
2.05% - 2.40
%
Expected term (in years)
 
 
10
 
 
6-10
 
Volatility
 
 
88
%
 
80%-82
%
 
Restricted Stock Units
 
Beginning in 2017, the Company issued restricted stock units (“RSUs”), to employees and non-employees as permitted by the 2014 Plan. Each restricted stock unit corresponds to one share of the Company’s common stock and becomes issuable upon vesting. The fair value of restricted stock units is determined based on the closing price of the Company’s common stock on the date of grant.
 
RSU activity for the three months ended March 31, 2018 is summarized below:
 
 
 
Number of Shares
 
Weighted- Average Grant Date Fair Value
 
Unvested as of January 1, 2018
 
 
617
 
$
1.65
 
Granted
 
 
35
 
$
1.73
 
Vested
 
 
(466)
 
$
1.32
 
Forfeited
 
 
(61)
 
$
2.85
 
Unvested at March 31, 2018
 
 
125
 
$
2.27
 
 
As of March 31, 2018, $159 of total unrecognized compensation expense related to unvested RSUs was expected to be recognized over a weighted average period of 2.96 years.
 
Compensation Expense
 
Total stock-based compensation expense related to options and RSUs granted to employees and non-employees is included in the condensed consolidated statements of operations and comprehensive loss as follows:
 
 
 
Three months ended March 31,
 
 
 
2018
 
2017
 
Sales and marketing
 
$
109
 
$
20
 
Research and development
 
 
179
 
 
101
 
General and administrative
 
 
604
 
 
273
 
 
 
$
892
 
$
394
 
 
401(k) Plan Share Match
 
In August 2017, the Company’s Board of Directors approved a match benefit to the Ekso Bionics 401(k) plan (the “401(k) Plan”) in the form of shares of the Company’s common stock. The Company will make a matching contribution to the 401(k) Plan in an amount equal to 100% of each eligible employee’s elected deferral (up to the statutory limit) for the year ending December 31, 2017 and equal to 50% of each employee’s elected deferral for each year thereafter.
 
During the three months ended March 31, 2018, the Company issued 221 shares of common stock to each eligible employee’s deferral account for the 401(k) Plan matching contribution for the year ended December 31, 2017.